• 1.

    Izmirly PM, et al. Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: Data from the Accelerating Medicines Partnership Lupus Network. Arthritis Res Ther 2024; 26:54. doi: 10.1186/s13075-024-03275-z

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    GlaxoSmithKline (GSK). FDA approves GSK's Benlysta as the first medicine for adult patients with active lupus nephritis in the United States. December 17, 2020. Accessed March 14, 2024. https://www.gsk.com/en-gb/media/press-releases/fda-approves-gsk-s-benlysta-as-the-first-medicine-for-adult-patients-with-active-lupus-nephritis-in-the-us/

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Aurinia. FDA approves Aurinia Pharmaceuticals’ Lupkynis™ (voclosporin) for adult patients with active lupus nephritis. January 22, 2021. Accessed March 14, 2024. https://www.auriniapharma.com/investors-and-media/news-events/press-releases/detail/210/fda-approves-aurinia-pharmaceuticals-lupkynis

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Kidney Disease: Improving Global Outcomes (KDIGO). Lupis nephritis (LN). January 3, 2024. Accessed March 14, 2024. https://kdigo.org/guidelines/lupus-nephritis/

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:S1S276. doi: 10.1016/j.kint.2021.05.021

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    GlaxoSmithKline (GSK). GSK for you. GSK pricing information: Benlysta. Accessed March 14, 2024. https://www.gskforyou.com/gsk-pricing-information/

  • 7.

    Drugs.com. Lupkynis prices, coupons and patient assistance programs. Accessed March 14, 2024. https://www.drugs.com/price-guide/lupkynis

  • 8.

    Institute for Clinical and Economic Review (ICER). Lupus nephritis: An assessment of voclosporin and belimumab. March 2021. Accessed March 14, 2024. https://icer.org/assessment/lupus-nephritis-2021/

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Carlucci PM, et al. High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. Rheumatology (Oxford) 2022; 61:43354343. doi: 10.1093/rheumatology/keac067

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Fava A, et al. Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI Insight 2024; 9:e172569. doi: 10.1172/jci.insight.172569

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Fava A, et al. Urine proteomics and renal single-cell transcriptomics implicate interleukin-16 in lupus nephritis. Arthritis Rheumatol 2022; 74:829839. doi: 10.1002/art.42023

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Fava A, et al. Integrated urine proteomics and renal single-cell genomics identify an IFN-γ response gradient in lupus nephritis. JCI Insight 2020; 5:e138345. doi: 10.1172/jci.insight.138345

    • PubMed
    • Search Google Scholar
    • Export Citation

Lupus Nephritis Guideline Updated to Advance Care, Reflect New Therapies

Bridget M. Kuehn
Search for other papers by Bridget M. Kuehn in
Current site
Google Scholar
PubMed
Close
Restricted access
Save